The American Cancer Society’s Report on the Status of Cancer Disparities in the United States examines disparities in cancer occurrence and outcomes, and analyzes the factors that contribute to these ...
Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...
Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...
Highlights in ER-positive breast cancer from SABCS 2025 include key metastatic and early-stage trial results from AMBRE, ...
Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback